Last updated: August 6, 2026
Avandaryl, GlaxoSmithKline’s fixed-dose combination of rosiglitazone and glimepiride, had limited commercial durability despite FDA approval in 2006. The product entered a type 2 diabetes market already supplied by inexpensive generic sulfonylureas and faced escalating cardiovascular-safety concerns surrounding rosiglitazone. Its financial trajectory was therefore tied to the rapid deterioration of the broader Avandia franchise rather than to strong product-level growth.
Public filings did not report Avandaryl revenue separately. GSK disclosed Avandia, Avandamet, and Avandaryl largely within franchise-level results, preventing a reliable standalone revenue series. The product’s commercial value declined sharply after 2007, and U.S. marketing was discontinued as demand, prescribing access, and differentiation weakened.
What is Avandaryl and how does it work?
Avandaryl combines:
| Component |
Drug class |
Role |
| Rosiglitazone maleate |
Thiazolidinedione, or TZD |
Improves insulin sensitivity through PPAR-gamma activation |
| Glimepiride |
Sulfonylurea |
Stimulates pancreatic insulin secretion |
The FDA approved Avandaryl tablets in 2006 as an adjunct to diet and exercise for adults with type 2 diabetes whose glycemic control was inadequate on either component alone. The product was available in multiple strengths combining rosiglitazone with glimepiride.[1]
The combination offered dosing convenience but limited clinical differentiation. Both active ingredients were already available as separate products, and physicians could titrate each drug independently. That reduced the value of a fixed-dose combination when safety concerns made rosiglitazone less attractive.
When did Avandaryl lose exclusivity?
Avandaryl’s commercial exclusivity weakened through a combination of patent expiry, generic substitution, regulatory restrictions, and declining physician demand.
The relevant exclusivity timeline was:
| Event |
Date |
Commercial effect |
| FDA approval of Avandaryl |
2006 |
U.S. commercial launch |
| Peak concern over rosiglitazone cardiovascular risk |
2007-2010 |
Reduced prescribing and payer acceptance |
| FDA safety restrictions and REMS |
2010 |
Major reduction in eligible prescribing |
| FDA modification of restrictions |
2013 |
Restrictions eased but market confidence remained damaged |
| Rosiglitazone product decline |
2011 onward |
Lower demand for Avandaryl and related products |
| U.S. commercial discontinuation |
Early 2010s |
Effectively ended the product’s U.S. revenue contribution |
The commercial protection of Avandaryl did not depend only on the expiration of a single combination-product patent. Its economic moat was already impaired by the availability of generic rosiglitazone and glimepiride as separate medicines, along with the loss of the rosiglitazone franchise’s safety reputation.
What patents protected Avandaryl?
Avandaryl’s protection was based on a combination of rights covering rosiglitazone, formulations, combination products, and regulatory exclusivity. The relevant patent estate was weaker than the patent estate for a new chemical entity because the active ingredients were established compounds.
Rosiglitazone and combination-product protection
Rosiglitazone originated within GSK’s broader Avandia patent program. Patent rights could cover:
- The rosiglitazone active ingredient
- Pharmaceutical compositions
- Dosage forms
- Combination treatment with other antidiabetic agents
- Methods for treating type 2 diabetes
- Specific fixed-dose combinations with sulfonylureas
Avandaryl’s protection was commercially vulnerable because the two active ingredients could be prescribed separately. A generic manufacturer did not need to replicate the entire commercial strategy to compete for the same patients.
Orange Book status
Avandaryl was listed in the FDA’s Orange Book during its marketed life, but the product’s commercial significance was limited by the decline of the underlying rosiglitazone franchise. Orange Book patent listings for a discontinued or no-longer-marketed product do not necessarily indicate an active commercial barrier.
A current patent-by-patent Orange Book determination requires the FDA’s live product and patent databases. The public historical record supports the conclusion that Avandaryl no longer has meaningful U.S. market exclusivity.
What was the FDA regulatory status of Avandaryl?
Avandaryl received FDA approval through a standard new drug application for a fixed-dose oral diabetes product.[1] Its regulatory position deteriorated after safety findings associated with rosiglitazone.
In 2010, the FDA imposed significant restrictions on rosiglitazone use through a Risk Evaluation and Mitigation Strategy. The restrictions limited prescribing and dispensing to patients and prescribers meeting specific conditions. The agency later removed or reduced several restrictions in 2013 after reviewing additional cardiovascular data, but the reversal did not restore the product to its previous market position.[2]
The key regulatory issue was class-specific rather than caused by glimepiride. Rosiglitazone was associated with concerns involving myocardial infarction and cardiovascular risk. The controversy affected Avandia, Avandamet, and Avandaryl because each product contained rosiglitazone.
How did safety concerns affect Avandaryl sales?
Safety concerns were the central driver of Avandaryl’s decline.
Before the regulatory crisis, rosiglitazone was one of the leading branded oral diabetes therapies. The franchise benefited from strong physician awareness, broad use in type 2 diabetes, and a substantial marketing infrastructure. Concerns regarding cardiovascular events altered the risk-benefit assessment and encouraged switching to other therapies.
The impact on Avandaryl was amplified by four factors:
- Glimepiride was available as an inexpensive generic.
- Rosiglitazone was no longer viewed as a preferred insulin-sensitizing option.
- Physicians could use alternative combinations without rosiglitazone.
- Payors had limited incentive to preserve coverage for a branded fixed-dose product.
Easing the FDA restrictions did not reverse these factors. Once physicians changed prescribing habits, a regulatory correction alone was insufficient to rebuild demand.
What was Avandaryl’s financial trajectory?
Avandaryl did not generate a separately disclosed revenue stream in GSK’s principal public financial reporting. GSK generally reported Avandia-related products at the franchise level or within broader diabetes reporting. This prevents a precise product-level revenue calculation.
The financial trajectory can be reconstructed directionally:
| Period |
Financial position |
Principal driver |
| 2006-2007 |
Growth opportunity within the Avandia franchise |
Launch of fixed-dose combination |
| 2008-2009 |
Declining growth and increasing risk discount |
Cardiovascular safety debate |
| 2010-2011 |
Sharp deterioration |
FDA restrictions and reduced prescribing |
| 2012-2014 |
Minimal commercial relevance |
Generic pressure and franchise withdrawal |
| Later period |
No material branded U.S. revenue contribution |
Discontinuation and loss of demand |
GSK’s overall Avandia franchise had reached multibillion-dollar annual sales before the safety crisis, but those figures included Avandia and Avandamet and cannot be assigned to Avandaryl. Avandaryl was a smaller product within that franchise because it launched later and competed against separate generic component therapy.
The product’s financial exposure was therefore asymmetric. It added incremental revenue during the franchise’s expansion but did not create a durable standalone market. Once rosiglitazone demand collapsed, Avandaryl lost most of its economic value.
How did Avandaryl compare with competing diabetes drugs?
Avandaryl competed against both branded therapies and low-cost generic regimens.
| Therapy |
Competitive advantage over Avandaryl |
Competitive weakness |
| Metformin plus sulfonylurea |
Low cost and established use |
Less convenient dosing |
| Pioglitazone-based therapy |
Similar insulin-sensitizing mechanism without the same rosiglitazone controversy at the time |
Class-level weight gain and edema concerns |
| DPP-4 inhibitors |
Better tolerability profile and newer branding |
Higher cost |
| GLP-1 receptor agonists |
Weight-loss and glycemic benefits |
Injectable administration and higher cost |
| SGLT2 inhibitors |
Cardiovascular and renal outcome advantages in later years |
Higher cost and newer safety considerations |
| Separate glimepiride plus another agent |
Flexible titration and generic pricing |
No fixed-dose convenience |
Avandaryl’s principal advantage was convenience. Its principal disadvantages were the rosiglitazone safety profile, inability to independently adjust each component, weight gain and hypoglycemia concerns, and the availability of low-cost alternatives.
What generic entry risks existed for Avandaryl?
Generic entry risk was high even before formal combination-product competition emerged.
Substitution through component products
A manufacturer could compete indirectly by selling generic glimepiride and generic rosiglitazone separately. This strategy did not require approval of an identical fixed-dose combination. Physicians and pharmacists could reproduce the therapeutic components through separate prescriptions.
Fixed-dose combination approval
A generic version of Avandaryl would require an abbreviated new drug application demonstrating bioequivalence to the reference product and addressing any listed patents or exclusivity. The economic incentive was weak because:
- The reference product had limited demand.
- Rosiglitazone prescribing had contracted.
- Generic component products were inexpensive.
- The fixed-dose combination offered modest differentiation.
- Marketing and reimbursement support had eroded.
Paragraph IV challenges
There is no widely reported, commercially consequential Paragraph IV litigation campaign associated with Avandaryl comparable to major blockbuster drugs. That absence is consistent with the product’s limited expected return. A Paragraph IV challenge is most attractive when the branded product has substantial remaining sales and a credible launch opportunity. Avandaryl’s sales base had already deteriorated before a generic challenger could capture meaningful value.
What patent litigation affected Avandaryl?
No major publicly prominent patent litigation materially shaped Avandaryl’s commercial trajectory. The product’s decline was driven primarily by regulatory action, safety concerns, and market substitution rather than by a decisive patent judgment.
The more relevant legal issues were:
- Product-liability litigation involving rosiglitazone
- Regulatory disputes and safety-label changes
- Commercial withdrawal and supply decisions
- Generic substitution risk
- Patent expiry affecting the underlying active ingredients
These matters had a larger financial effect than litigation over the Avandaryl combination itself.
Did GSK license Avandaryl or the underlying technology?
Avandaryl was developed and commercialized within GSK’s rosiglitazone franchise. No major third-party licensing transaction is generally identified as a principal value driver for Avandaryl.
The product’s commercial economics were controlled by GSK’s ownership of the rosiglitazone program, regulatory rights, manufacturing network, and brand portfolio. Licensing was not the main determinant of market performance.
What manufacturing and intellectual-property barriers protected Avandaryl?
Manufacturing barriers were low relative to biologics or complex drug-device products. Avandaryl was an oral immediate-release tablet containing two established small-molecule active ingredients. A competitor would face standard pharmaceutical development requirements rather than difficult biologic manufacturing or specialized delivery technology.
Potential manufacturing considerations included:
- Consistent content uniformity for two active ingredients
- Stability of the fixed-dose tablet
- Dissolution and bioequivalence testing
- Control of tablet strength and batch reproducibility
- Regulatory validation for combination-product manufacturing
These requirements created execution obligations but did not form a durable barrier. The absence of biologic complexity and the availability of generic active ingredients limited manufacturing-based protection.
How strong was the Avandaryl patent estate?
Avandaryl had a moderate historical patent position but weak long-term commercial strength.
| Strength factor |
Assessment |
| New chemical entity protection |
Limited for the combination product |
| Active-ingredient differentiation |
Low, because both ingredients were established |
| Fixed-dose convenience |
Real but modest |
| Formulation complexity |
Low |
| Method-of-use breadth |
Potentially meaningful but vulnerable to component substitution |
| Regulatory protection |
Short relative to the product’s commercial decline |
| Litigation deterrence |
Limited evidence of major enforcement |
| Post-safety commercial value |
Low |
The estate may have delayed direct generic substitution, but it could not prevent therapeutic substitution. That distinction is critical. Avandaryl’s commercial protection depended on continued demand for rosiglitazone, and the safety crisis destroyed that demand faster than patent expiry alone would have done.
What is the current competitive and commercial outlook for Avandaryl?
Avandaryl has no meaningful current competitive growth profile in the U.S. Its market has been displaced by generic component therapy and newer diabetes medicines with stronger clinical-outcome positioning.
The competitive landscape now favors:
- Generic metformin and sulfonylureas for low-cost treatment
- SGLT2 inhibitors for patients with cardiovascular or renal risk
- GLP-1 receptor agonists for glycemic control and weight management
- DPP-4 inhibitors for selected tolerability-driven use
- Insulin and other therapies for advanced disease
The product’s residual value is primarily historical, regulatory, and intellectual-property related. It is not a credible growth asset absent a major change in prescribing standards, safety perception, or commercial strategy.
Key Takeaways
- Avandaryl is the fixed-dose rosiglitazone/glimepiride combination developed by GSK and approved by the FDA in 2006.
- Its commercial decline was driven primarily by rosiglitazone cardiovascular-safety concerns and FDA restrictions.
- GSK did not separately disclose Avandaryl revenue, so product-level sales cannot be reliably quantified from public filings.
- The combination had limited differentiation because physicians could prescribe generic rosiglitazone and glimepiride separately.
- The product faced high substitution risk but limited economic incentive for a major Paragraph IV challenge.
- No major patent litigation materially determined Avandaryl’s market outcome.
- Avandaryl’s U.S. commercial relevance ended in the early 2010s, and its current market value is negligible.
- The product illustrates the weakness of formulation convenience when the principal active ingredient loses regulatory and clinical acceptance.
FAQs About Avandaryl
Is Avandaryl still available in the United States?
Avandaryl is not a meaningful actively marketed U.S. product. Its commercial withdrawal followed the decline of the rosiglitazone franchise.
What are the active ingredients in Avandaryl?
Avandaryl contains rosiglitazone maleate and glimepiride.
Is there a generic version of Avandaryl?
Separate generic rosiglitazone and glimepiride products can reproduce the active ingredients, but the commercial market for an identical fixed-dose generic combination is limited.
Why did Avandaryl sales decline?
Sales declined because of cardiovascular-safety concerns involving rosiglitazone, FDA prescribing restrictions, physician switching, generic competition, and the availability of newer diabetes treatments.
Did Avandaryl have biologic or complex-manufacturing protection?
No. Avandaryl was a conventional oral small-molecule tablet. Its manufacturing requirements did not create the type of barrier associated with biologics, inhaled products, or complex drug-delivery systems.
References
-
U.S. Food and Drug Administration. (2006). Avandaryl prescribing information. FDA.
-
U.S. Food and Drug Administration. (2013). FDA drug safety communication: FDA eliminates the Risk Evaluation and Mitigation Strategy for rosiglitazone-containing diabetes medicines. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
GlaxoSmithKline plc. (2007-2014). Annual reports and financial statements. GSK.
-
U.S. Senate Committee on Finance. (2010). The marketing, promotion, and advertising of the prescription drug Avandia. United States Senate.
